French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
XBiotech to Supply INSERM its New Drug to Use in Combination Therapy for Treating Advanced Colorectal Cancer
AUSTIN, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that it had reached an agreement to supply its new cancer drug XB20-01 to INSERM, and its Federation of Digestive Oncology group, a French organization which supports world-leading innovation for treating colorectal cancer.
Colorectal is one of the most common forms of cancer in Europe and the United States, with nearly 150,000 new cases and 53,000 deaths expected in the US alone in 2021. The current chemotherapy regimen uses a Trifluridine/Tipiracil combination, drugs that interfere with the genetic material of cells in an effort to kill tumors. However, inflammation and toxicity from the chemotherapy is offset only by modest response rates and less than ideal outcomes. Thus, there is significant unmet medical need for this group of colorectal cancer patients. XBiotech’s new drug candidate XB20-01 targets an inflammatory process potentially involved in the growth and spread of colorectal cancer; and the new drug may also block inflammation caused by chemotherapy, potentially reducing side effects and improving the treatment effect of chemotherapy.
The chair and lead investigator of the multicenter clinical study is Dr. François Ghiringhelli M.D. Ph.D, Director of INSERM, and Professor of Oncology at the University of Burgundy, Genetic and Immunotherapy Medical Institute. Dr. Ghiringhelli, a world-leading researcher in colorectal cancer, designed the study which features an innovative interim analysis to assess improvement in overall survival. If patients receiving XB20-01 have a predetermined improvement in survival compared to the placebo treated group, the randomized study will be expanded to enroll a phase III portion with overall survival as the primary outcome.
Professor Ghiringhelli, also a Director at the prestigious INSERM center and Head of a Division specializing in "Cancer and adaptive immune response", commented, “This is a very exiting clinical trial, granted by the French Cancer Institute, for a very frequent and devastating disease. Currently very few drugs give promising results for these patients. In case of success, this trial could be practice changing.”
John Simard CEO XBiotech stated, “We are honored to be able to provide our new candidate drug to INSERM, an institution that is setting a global standard for public involvement in the promotion of innovation in medicine. François has developed a brilliant study design that we are very excited to support.”
Cytotoxic chemotherapy agents result in systemic toxicity—considered to be a trade-off for potential anti-tumor activity. Toxicity is of acute importance clinically, but consequences of inflammatory responses induced by cytotoxic agents may also have a more profound impact, promoting tumor growth, and compromising the efficacy and durability of the therapy itself. Cytotoxic agents upregulate inflammatory pathways, including activation of leukocytes, vascular endothelium, and stromal cells of the tumor microenvironment. IL-1a is believed to play a key role in pro-tumor and treatment related inflammatory pathways.
XBiotech’s new drug XB20-01 is a naturally occurring antibody that potently neutralizes IL-1a and is thus a safe and promising approach to block inflammation that occurs with advanced malignancies and chemotherapy. Unchecked, IL-1a can stimulate angiogenesis, enhancing blood and nutrient supply to the tumor; IL-1a may also act to recruit unwanted leukocytes (such as myeloid suppressor cells) into the tumor, that can suppress the ability of the body’s immune system to fight off the tumor; and systemically, IL-1a can mediate metabolic dysfunction, and cause fatigue, anorexia, and anxiety in cancer patients. IL-1a is thus a unique target for addressing paraneoplastic inflammation—with XBiotech’s new drug therapy holding promise for treating a wide array of cancers.
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
New Management Appointments in Golar LNG Ltd.13.5.2021 15:05:36 CEST | Press release
The board of Golar LNG Limited ("Golar") is pleased to announce that they have appointed Mr. Karl Fredrik Staubo as the new Chief Executive Officer of the company in their board meeting on 13th May 2021. Mr. Staubo has since May 2020 been the Chief Executive Officer of Golar LNG Partners LP, recently successfully sold to New Fortress Energy. Since September 2020 Mr. Staubo has also been acting as Chief Financial Officer of Golar. Mr. Staubo has a broad shipping/energy background from Clarksons Platou Securities (2010-2018) and Magni Partners (2018-2020). He has a MA (Business Studies and Economics) from the University of Edinburgh. The board has in the same meeting also appointed Mr. Eduardo Maranhao to take over Mr. Staubo’s role as Chief Financial Officer of Golar. Mr. Maranhao has since 2015 been supporting Golar in different functions including as Chief Financial Officer of Golar Power/Hygo Energy Transition Limited until its recent sale to New Fortress Energy. Prior to joining the
Accumulus Synergy Appoint Francisco Nogueira as Chief Executive Officer13.5.2021 15:00:00 CEST | Press release
Accumulus is the first non-profit corporation designed to establish a relationship between technology, policy and collaboration between drug developers, NGOs, academic institutions and government agencies BURLINGAME, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Accumulus Synergy, a non-profit corporation intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, today announced the appointment of Francisco (Frank) Nogueira as the new chief executive officer (CEO). Mr. Nogueira was previously a vice president of Regulatory Affairs at Roche and served as interim CEO at Accumulus since the fall of 2020. Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities. The common-platform approach to data sharing aims to make the regulatory process more eff
Notification on convocation of the Joint Stock Company “Latvijas Gāze” Annual General Meeting of Shareholders13.5.2021 15:00:00 CEST | Press release
The Board of joint stock company “Latvijas Gāze”, registration number: 40003000642, legal address: Aristida Briana iela 6, Riga, LV-1001, Latvia (hereafter – the Company) calls up and announces that Annual General Meeting of Shareholders of the Company will take place on June 15, 2021 at 10.00 at the premises of the Company at Aristida Briana iela 6, Riga, LV-1001, Latvia using electronic means of communication. Agenda: Reports of the Board, the Council and the Audit Committee, and the certified auditor’s opinion.Approval of the Annual Report 2020.Distribution of the profit.Setting of remuneration to the members of the Council and the Audit Committee for the 2020 annual performance.Election of the auditor of the 2020 annual accounts and setting of remuneration to the auditor.Election of the Council and setting of remuneration to the Council. The record date for participation at the Annual General Meeting of Shareholders of the Company is June 7, 2021. Only those persons who are shareho
Vertex Acquires Taxamo to Expand Global Commerce and Compliance Solutions13.5.2021 13:30:00 CEST | Press release
European specialist in tax automation for e-commerce and marketplaces KING OF PRUSSIA, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of tax technology solutions, today announced it has acquired Taxamo, a cloud-based pioneer in tax and payment automation for global e-commerce and marketplaces. Taxamo, headquartered in Ireland, counts many of the leading, high-growth digital service providers among its global customers who rely on its unified platform of integrated capabilities to support indirect tax compliance, with a core focus on online sales, payments, and e-invoicing. “The fabric of today’s global commerce is more connected and complex than ever before,” said Vertex CEO David DeStefano. “Our mission is to enable every business to transact, comply and grow with confidence. We are incredibly excited to bring these new end-to-end solutions to our customers and partners around the world.” Taxamo’s cloud-based so
Results 2021 Annual General Meeting13.5.2021 08:30:00 CEST | Press release
PRESS RELEASE: Amsterdam – 13 May 2021.Intertrust N.V. (“Intertrust”) [Euronext: INTER], a global leader in providing tech-enabled corporate and fund solutions to clients operating and investing in international business, announces that in the Annual General Meeting of 12 May 2021 (2021AGM) the shareholders adopted all voting items on the agenda. At the 2021 AGM a total of 73.59% of the total issued share capital was represented. The results of the votes for each item on the agenda, will be published on our website https://www.intertrustgroup.com/investors/shareholder-information/annual-general-meeting-may-2021/ . Draft minutes of the 2021 AGM will be published no later than three months after the end of the meeting, after which shareholders should have the opportunity to react in the following three months. About Intertrust Intertrust has 4,000+ employees who are dedicated to providing world-leading, specialised administration services to clients in over 30 jurisdictions. This is ampl
Update on Kurdistan Payments13.5.2021 07:51:03 CEST | Press release
Oslo, 13 May 2021 – DNO ASA, the Norwegian oil and gas operator, today reported that Kurdistan’s Minister of Natural Resources has informed the international oil companies operating in the region of an intention to extend the payment period for arrears built up from non-payment of certain invoices in 2019 and 2020. As widely reported, last December the Prime Minister of Kurdistan announced a decision to pay the companies 50 percent of incremental revenue in any month in which Brent prices exceed USD 50 per barrel towards the arrears. The revised terms reduce the payment of the withheld amounts to 20 percent of incremental revenue above USD 50 per barrel. The Minister also advised that all international oil company invoices, including towards withheld amounts, will now be settled within 60 days of receipt. DNO is reviewing its position and will engage with Kurdistan to seek agreement regarding payment terms, interest on the arrears and revised lifting arrangements. – For further informa
Mandalay Resources Corporation Announces Financial Results for the First Quarter of 202113.5.2021 00:05:33 CEST | Press release
TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce its financial results for the quarter March 31, 2021. The Company’s condensed and consolidated interim financial results for the quarter ended March 31, 2021, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. First Quarter 2021 Highlights: Quarterly revenue of $52.6 million; highest since Q2 2016;Adjusted EBITDA of $26.1 million; third highest in Company’s history;Adjusted net income of $5.6 million ($0.06 or C$0.08 per share); andConsolidated net income of $25.5 million ($0.28 or C$0.35 per share). Dominic Duffy, President and CEO of Mandalay, commented: “Mandalay Resources is ple